Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00042055 · ClinicalTrials.gov registry record · Phase 2

CP-461 for the Treatment of Crohn's Disease

A Phase 2 study of Crohn's Disease, sponsored by Astellas Pharma.

Completed
Registry status
Phase 2
Development phase
30
Enrollment target
10
Study locations

NCT00042055: Completed Phase 2 study of Crohn's Disease, sponsored by Astellas Pharma.

NCT00042055 is a Phase 2 study of Crohn's Disease that has completed, run by Astellas Pharma. The registered enrollment target is 30 participants, below the 2,394-participant average among 105 other Crohn's Disease trials with a reported enrollment target (99% lower). The trial reports 10 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00042055, a Phase 2 study of Crohn's Disease, has completed, sponsored by Astellas Pharma.

COMPLETED
Registry status
Phase 2
Development phase
30 participants
Enrollment target
10
Study locations

Study Summary

Patients with moderately to severely active Crohn's disease will be treated with oral CP-461 200 mg (2 x 100 mg capsules) twice-daily for 8 weeks. The purpose of this study is to see if CP-461 improves the symptoms of Crohn's disease and/or the patient's quality of life. Patient's safety will be monitored throughout the study.

Conditions Studied

Crohn's Disease

Interventions

  • DRUG CP-461

Study Locations (10)

Alabama

  • Southern Drug Research - Birmingham

California

  • Community Clinical Trials - Orange

Florida

  • Florida Medical Research Institute, PA - Gainesville

Georgia

  • Atlanta Gastroenterology Associates - Atlanta

Illinois

  • University of Chicago Medical Center - Chicago

Indiana

  • Indianapolis Gastroenterology and Hepatology, Inc. - Indianapolis

Maryland

  • Digestive Disease Associates, PA - Columbia

New Jersey

  • Atlantic Gastroenterology Associates - Egg Harbor

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2002-07
Est. Completion 2003-09
Phase Phase 2
Astellas Pharma

165 total trials

What the finished NCT00042055 record still lists

NCT00042055 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 2,394-participant average among 105 other Crohn's Disease trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 1 intervention - of which CP-461 is the first listed.

NCT00042055 lists 10 locations in 10 states (Alabama, California, Florida).

Frequently Asked Questions

What is clinical trial NCT00042055 about?

NCT00042055 is a clinical study titled "CP-461 for the Treatment of Crohn's Disease". Patients with moderately to severely active Crohn's disease will be treated with oral CP-461 200 mg (2 x 100 mg capsules) twice-daily for 8 weeks. The purpose of this study is to see if CP-461 improves the symptoms of Crohn's disease and/or the patient's quality of life. Patient's safety will be mo...

What is the current status of trial NCT00042055?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2002-07. Estimated completion is 2003-09.

What conditions does trial NCT00042055 study?

This clinical trial studies the following conditions: Crohn's Disease.

What interventions are being tested in trial NCT00042055?

The interventions under investigation include: CP-461 (DRUG).

Who is sponsoring clinical trial NCT00042055?

This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00042055 being conducted?

This trial has 10 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Crohn's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00042055's enrollment target sits among peer trials

30 94th of 105 higher than 11 of 105 other Crohn's Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Crohn's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00042055, the US trial registry maintained by the National Library of Medicine. NCT00042055 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.